Parkinson’s Disease – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Parkinson's Disease – Pipeline Review, H1 2020’, provides an overview of the Parkinson's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Parkinson's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Parkinson's Disease

– The report reviews pipeline therapeutics for Parkinson's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Parkinson's Disease therapeutics and enlists all their major and minor projects

– The report assesses Parkinson's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Parkinson's Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

1st Bio Therapeutics Inc

4D Pharma Plc

Abaxy Sprl

AbbVie Inc

Abivax SA

ABL Bio Inc

AC Immune SA

Acelot Inc

AcuraStem Inc

Addex Therapeutics Ltd

Affichem SA

AFFiRiS AG

AgoneX Biopharmaceuticals Inc

Alan Laboratories Inc

Alector Inc

Alectos Therapeutics

Alexza Pharmaceuticals Inc

Alkahest Inc

Alkermes Plc

Allife Medical Science and Technology Co Ltd

AlphaCognition Inc

Alsonex Pty Ltd

Alterity Therapeutics Ltd

Amabiotics SAS

Amathus Therapeutics Inc

Amneal Pharmaceuticals Inc

Anavex Life Sciences Corp

Anida Pharma Inc

Annovis Bio Inc

Antoxis Ltd

Aoxing Pharmaceutical Company Inc

Apollo Therapeutics LLC

Appello Pharmaceuticals Inc

Aprinoia Therapeutics Inc

AptaBio Therapeutics Inc

Aptamer Sciences Inc

Araclon Biotech SL

Aranda Pharma Ltd

AriBio

ArmaGen Inc

Arrien Pharmaceuticals LLC

Arvinas Inc

Asdera LLC

Asklepios BioPharmaceutical Inc

Aspen Neuroscience Inc

Astellas Pharma Inc

AstraZeneca Plc

Athersys Inc

Athira Pharma Inc

Auritec Pharmaceuticals Inc

Avicanna Inc

Axial Biotherapeutics Inc

Axovant Gene Therapies Ltd

AZTherapies Inc

Azymus Therapeutics Inc

B&A Therapeutics

BCWorld Pharm Co Ltd

Belrose Pharma Inc

Berg LLC

Better Life Pharmaceuticals Inc

Bial – Portela & Ca SA

Bio-Modeling Systems SAS

Bio-Pharm Solutions Co Ltd

Bioasis Technologies Inc

Biogen Inc

BlueRock Therapeutics

BrainStorm Cell Therapeutics Inc

Bristol-Myers Squibb Co

C4X Discovery Holdings Plc

Calico LLC

Califia Bio Inc

Cantabio Pharmaceuticals Inc

Canvax Biotech SL

Capo Therapeutics Inc

Carmot Therapeutics Inc

Carna Biosciences Inc

Cavion LLC

CavoGene LifeSciences

Celavie Biosciences LLC

CellCure

Cellivery Therapeutics Inc

Cellix Bio Pvt Ltd

Cerecin Inc

Cerecor Inc

CereSpir Inc

Cerevance Inc

Cerevel Therapeutics LLC

CHA Biotech Co Ltd

Chase Therapeutics Corp

Chiesi Farmaceutici SpA

Chipscreen Biosciences Ltd

CholesteniX Ltd

Chongqing Pharmaceutical Research Institute Co Ltd

Ci Therapeutics

Clayton Biotechnologies Inc

Clene Nanomedicine Inc

Clevexel Pharma SAS

Cogentis Therapeutics Inc

Collaborative Medicinal Development LLC

Contera Pharma ApS

Copernicus Therapeutics Inc

Corium, Inc.

Crossject SA

CuraSen Therapeutics Inc

Curemark LLC

CuroNZ Ltd

Curyx Bio Inc

Cypralis Ltd

Dadang & BIO Co Ltd

DanPET AB

Declion Pharmaceuticals Inc

DegenRx BV

Denali Therapeutics Inc

DermaXon LLC

Diffusion Pharmaceuticals Inc

Dina Pharmaceuticals Inc

Dizlin Medical Design AB

Domain Therapeutics SA

DongKoo Bio & Pharma Co Ltd

E-scape Bio Inc

Easywell Biomedical Inc

Eisai Co Ltd

Eli Lilly and Co

Emerald Health Sciences Inc

Emerald Organic Products Inc

Energenesis Biomedical Co Ltd

Evgen Pharma Plc

Fabre-Kramer Pharmaceuticals Inc

Fortuna Fix Inc

Fulcrum Therapeutics Inc

GB Sciences Inc

Generoath Co Ltd

Genervon Biopharmaceuticals LLC

GenKyoTex SA

Genmab AS

Genzyme Corp

Gismo Therapeutics Inc

Global BioLife Inc Ltd

GNT Pharma Co Ltd

Grespo AB

GT Gain Therapeutics SA

Guangzhou Magpie Pharmaceutical Co Ltd

H. Lundbeck AS

Hebei Newtherapy BIo-Pharma Technology Co Ltd

Herantis Pharma Plc

HitGen LTD

Hong Kong WD Pharmaceutical Co Ltd

Hope Biosciences LLC

Icagen Inc

ICB International Inc

Icure Pharmaceutical Inc

Imago Pharmaceuticals Inc

Immune Modulation Inc

Immungenetics AG

Impel NeuroPharma Inc

Inexia Ltd

Inflazome Ltd

Inhibikase Therapeutics Inc

InnoMedica Holding AG

Intec Pharma Ltd

International Stem Cell Corp

Intra-Cellular Therapies Inc

Invisio Ltd

Io Therapeutics Inc

Ionis Pharmaceuticals Inc

IRLAB Therapeutics AB

Jazz Pharmaceuticals Plc

Jeil Pharmaceutical Co Ltd

Junaxo Inc

Kainos Medicine Inc

Kariya Pharmaceuticals IVS

Kashiv BioSciences LLC

Keapstone Therapeutics Ltd

Kissei Pharmaceutical Co Ltd

Kyowa Kirin Co Ltd

Lauren Sciences LLC

Lead Discovery Center GmbH

Living Cell Technologies Ltd

Longevity Biotech Inc

Luye Pharma Group Ltd

Lysosomal Therapeutics Inc

Macrobian Biotech BV

Mavalon Therapeutics Ltd

MD Healthcare Inc

Med-Life Discoveries LP

MedGenesis Therapeutix Inc

MeiraGTx Holdings Plc

Merck & Co Inc

Meta-IQ ApS

Metabolic Solutions Development Company LLC

MetiMedi Pharmaceuticals Co Ltd

MetVital Inc

MimeTech Srl

Minerva Neurosciences Inc

Mission Therapeutics Ltd

Mitochon Pharmaceuticals Inc

Mitoconix Bio Ltd

MitoDys Therapeutics Ltd

Mitokinin LLC

Mitsubishi Tanabe Pharma Corp

Modag GmbH

Montisera Ltd

Motac Neuroscience Ltd

Neonc Technologies Inc

Netherlands Translational Research Center BV

NeuBase Therapeutics Inc

NeuExcell Therapeutics Inc

Neuracle Science Co Ltd

Neuraly Inc

Neuren Pharmaceuticals Ltd

Neuro Vigor LLC

Neurocea Pharmaceuticals

Neurochlore

Neurodon LLC

Neuroene Therapeutics LLC

NeuroGeneration Inc

Neurona Therapeutics Inc

NeuroNascent Inc

NeuroPn Therapeutics LLC

Neuropore Therapies Inc

Neurotrope Bioscience Inc

New Amsterdam Sciences Inc

New Biotic Inc

New World Laboratories Inc

Newron Pharmaceuticals SpA

Nitrome Biosciences Inc

nLife Therapeutics SL

NLS Pharma Group

Novartis AG

Novo Nordisk AS

NTZ Lab Ltd

NutriBand Inc

Omeros Corp

Oncodesign SA

Orphazyme A/S

Orpheris Inc

Oryzon Genomics SA

Oxyrane Belgium NV

Parkure Ltd

Peptron Inc

Pfizer Inc

Pharma Two B Ltd

PharmatrophiX Inc

Pharmicell Co Ltd

Phoenix Biotechnology Inc

Phoenix Life Sciences International Ltd

PK Biosciences Corp

Plex Pharmaceuticals Inc

Polaryx Therapeutics Inc

PolyCore Therapeutics LLC

Prevail Therapeutics Inc

Priavoid GmbH

Primary Peptides Inc

Proclara Biosciences Inc

ProMIS Neurosciences Inc

Promius Pharma LLC

Prothena Corp Plc

Prous Institute for Biomedical Research SA

Psy Therapeutics Inc

PTC Therapeutics Inc

reMYND NV

Renown Pharmaceuticals Pvt Ltd

resTORbio Inc

Retrotope Inc

Revalesio Corp

Rich Pharmaceuticals Inc

Rionis LLC

Sage Therapeutics Inc

SalubRx Therapeutics Inc

SanBio Inc

Sandoz International GmbH

Saniona AB

Sanofi

Seelos Therapeutics, Inc.

Seneb BioSciences Inc

Sengenics International Pte Ltd

Serina Therapeutics Inc

Shanghai Angecon Biotechnology Corp

Shenox Pharmaceuticals LLC

Shift Bioscience Ltd

SignPath Pharma Inc

Sinfonia Biotherapeutics Inc

Sorrento Therapeutics Inc

SparkBioPharma Inc

STATegics Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Sunovion Pharmaceuticals Inc

Suven Life Sciences Ltd

Synthonics Inc

Takeda Pharmaceutical Co Ltd

Tarus Therapeutics Inc

TauRx Therapeutics Ltd

Techfields Pharma Co Ltd

TechnoPhage SA

Teikoku Pharma USA Inc

Tranquis Therapeutics Inc

TreeFrog Therapeutics SAS

Treventis Corp

Trucode Gene Repair Inc

UCB SA

UniQure NV

United Neuroscience Ltd

Varinel Inc

Verge Genomics Inc

Videns Incorp Ltd

Vivreon Biosciences LLC

Voyager Therapeutics Inc

WhanIn Pharmaceutical Co Ltd

Xcelthera INC

Xoc Pharmaceuticals Inc

XYnapse Therapeutics Pty Ltd

Yuhan Corp

Yumanity Therapeutics

Zhittya Genesis Medicine Inc

Table of Contents

Table of Contents

Introduction

Parkinson's Disease - Overview

Parkinson's Disease - Therapeutics Development

Parkinson's Disease - Therapeutics Assessment

Parkinson's Disease - Companies Involved in Therapeutics Development

Parkinson's Disease - Drug Profiles

Parkinson's Disease - Dormant Projects

Parkinson's Disease - Discontinued Products

Parkinson's Disease - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Parkinson's Disease, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..6), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..7), H1 2020

List of Figures

List of Figures

Number of Products under Development for Parkinson's Disease, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports